Coya Therapeutics announced that the 100th patient has been enrolled in its Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for amyotrophic lateral sclerosis. The company anticipates completing full enrollment of 120 participants to permit reporting top-line data in early Q2 2027. Coya Therapeutics operates in the biotechnology industry, developing immunotherapies for neurological diseases.
